Skip to Content
  • Previous Rank
    69
  • Revenues ($M)
    $40,122.00
  • Revenue Percent Change
    0.8%
  • Profits ($M)
    $2,394.00
  • Profits Percent Change
    -38.9%
  • Assets ($M)
    $87,872.00
  • Employees
    69,000
  • Market Value — as of March 29, 2018 ($M)
    $146,861.50

The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year–an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy has been recently halted.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Kenneth C. Frazier
CEO Title
Chairman, President & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, N.J.
Websitehttp://www.merck.com
Years on Fortune 500 List24
Employees69,000

Merck Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$40,122.000.8%
Profits ($M)$2,394.00-38.9%
Assets ($M)$87,872.00-
Total Stockholder Equity ($M)$34,336.00-
Market Value — as of March 29, 2018 ($M)$146,861.50-

Profit Ratios

Profit as % of Revenues6%
Profits as % of Assets2.7%
Profits as % of Stockholder Equity7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)0.87
EPS % Change (from 2016)-38.3%
EPS % Change (5 year annual rate)-15.3%
EPS % Change (10 year annual rate)-5.2%

Total Return

Total Return to Investors (2017)-1.5%
Total Return to Investors (5 year, annualized)10.1%
Total Return to Investors (10 year, annualized)3.5%